@Justanovice - "This one definitely requires patience and a long...

@Justanovice - "This one definitely requires patience and a long term view. The market is often irrational in both directions in the short term. Sometimes I wonder why anyone who knows the background would sell at 9.4c today given recent news, but as some have said, if you bought recently at 6c, that’s pretty good going"
Couldn't agree more that patience is definitely required on BOT. I am a long term holder since late 2017 and my personal view is who have been accumulating given recent news
1. There have been no short sell activities since 08/12/2022 the announcement of Confirmation Sofpironium Bromide NDA Formally Under Review,(refer to attached Short Sales chart from Shortman.com.au)
2.BOT's current Mket Cap is $125 million. Broker Euroz Hartleys Report dated 01/02/2023- the market has paid ~A$110-600 million on FDA NDA filing day(pre- FDA approval) and ~A$250-2,500 million upon FDA approval. Analyst Seth Lizée noted the experience of the Botanix team in securing FDA-approval, and successfully commercialising over 30 products. He classified Botanix as a ‘Speculative Buy, Target Price $0.27’, commenting:
3. 03/04/2023 - FDA Mid-Cycle Review Meeting Successfully Completed
4. 13/04/2013 - Botanix successfully completes A$10m Placement - Botanix Executive Chair Vince Ippolito said: With the FDA mid-cycle review successfully behind us and FDA approval for Sofpironium Bromide on track for approval in September 2023, we have a very busy period ahead of us to prepare for launch ofthe product.

this is not a financial advice